- Home
- BOE vs PHAR Comparison
BOE vs PHAR Comparison
Compare BOE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOE
- PHAR
- Stock Information
- Founded
- BOE 2005
- PHAR 1988
- Country
- BOE United States
- PHAR Netherlands
- Employees
- BOE N/A
- PHAR N/A
- Industry
- BOE Trusts Except Educational Religious and Charitable
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- BOE Finance
- PHAR Health Care
- Exchange
- BOE Nasdaq
- PHAR Nasdaq
- Market Cap
- BOE 686.0M
- PHAR 627.5M
- IPO Year
- BOE N/A
- PHAR N/A
- Fundamental
- Price
- BOE $11.19
- PHAR $8.18
- Analyst Decision
- BOE
- PHAR Strong Buy
- Analyst Count
- BOE 0
- PHAR 2
- Target Price
- BOE N/A
- PHAR $33.50
- AVG Volume (30 Days)
- BOE 166.1K
- PHAR 6.6K
- Earning Date
- BOE 01-01-0001
- PHAR 10-24-2024
- Dividend Yield
- BOE 7.30%
- PHAR N/A
- EPS Growth
- BOE N/A
- PHAR N/A
- EPS
- BOE N/A
- PHAR N/A
- Revenue
- BOE N/A
- PHAR $285,745,000.00
- Revenue This Year
- BOE N/A
- PHAR $20.89
- Revenue Next Year
- BOE N/A
- PHAR $11.15
- P/E Ratio
- BOE N/A
- PHAR N/A
- Revenue Growth
- BOE N/A
- PHAR 30.64
- 52 Week Low
- BOE $8.80
- PHAR $6.65
- 52 Week High
- BOE $10.48
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- BOE 48.13
- PHAR 47.63
- Support Level
- BOE $11.09
- PHAR $7.70
- Resistance Level
- BOE $11.39
- PHAR $8.28
- Average True Range (ATR)
- BOE 0.13
- PHAR 0.41
- MACD
- BOE -0.01
- PHAR -0.07
- Stochastic Oscillator
- BOE 45.12
- PHAR 44.27
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.